Literature DB >> 33571391

Incidence of and Risk Factors for Heart Failure in Patients With Psoriatic Disease: A Cohort Study.

Sahil Koppikar1, Keith Colaco2, Paula Harvey1, Shadi Akhtari1, Vinod Chandran3, Dafna D Gladman3, Richard Cook4, Lihi Eder1.   

Abstract

OBJECTIVE: To assess the incidence and risk factors for heart failure in patients with psoriatic disease and to describe their electrocardiographic and echocardiographic findings.
METHODS: A cohort analysis was conducted involving patients with psoriatic disease followed prospectively from 1978 to 2018. Participants were assessed according to a standard protocol every 6 to 12 months. The primary outcome was the time to first event of heart failure, further classified into ischemic and nonischemic heart failure (secondary outcomes). The association between cardiovascular risk factors, measures of disease activity, and heart failure events was assessed using Cox proportional hazards regression. Electrocardiographic and echocardiographic findings associated with heart failure events were described.
RESULTS: A total of 1,994 patients with psoriatic disease were analyzed, with 64 incident heart failure events (38 ischemic, 26 nonischemic). The incidence rate of first heart failure event was 2.85 per 1,000 patient-years. In all events, the most common electrocardiographic findings were atrial fibrillation (22%) and bundle branch blocks (29%). Echocardiogram revealed 37% reduced ejection fraction and 63% preserved ejection fraction. In multivariable analysis, independent risk factors for all heart failure events were ischemic heart disease, adjusted mean tender joint count, adjusted mean swollen joint count, adjusted mean erythrocyte sedimentation rate, adjusted mean C-reactive protein level, and physical function (by Health Assessment Questionnaire) (all P < 0.05). Minimal disease activity state was protective for all heart failure (P < 0.05).
CONCLUSION: Increased risk of heart failure is associated with a combination of known cardiovascular risk factors and measures of disease activity, particularly in nonischemic heart failure. The effect of inflammation on heart failure may be partially independent of atherosclerotic disease.
© 2021 American College of Rheumatology.

Entities:  

Mesh:

Year:  2022        PMID: 33571391     DOI: 10.1002/acr.24578

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   5.178


  4 in total

1.  The relationship between systemic inflammation and increased left ventricular mass is partly mediated by noncalcified coronary artery disease burden in psoriasis.

Authors:  Wunan Zhou; Meron Teklu; Vy Bui; Grigory A Manyak; Promita Kapoor; Amit K Dey; Alexander V Sorokin; Nidhi Patel; Heather L Teague; Martin P Playford; Julie Erb-Alvarez; Justin A Rodante; Andrew Keel; Sujata M Shanbhag; Li-Yueh Hsu; David A Bluemke; Marcus Y Chen; Marcus Carlsson; Nehal N Mehta
Journal:  Am J Prev Cardiol       Date:  2021-05-30

2.  Comparison of the risk of heart failure in psoriasis patients using anti-TNF α inhibitors and ustekinumab.

Authors:  Ju Hee Han; Hae Eun Park; Yeong Ho Kim; Jin-Hyung Jung; Ji Hyun Lee; Young Min Park; Chul Hwan Bang
Journal:  ESC Heart Fail       Date:  2022-02-17

3.  Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study.

Authors:  Keith Colaco; Ker-Ai Lee; Shadi Akhtari; Raz Winer; Paul Welsh; Naveed Sattar; Iain B McInnes; Vinod Chandran; Paula Harvey; Richard J Cook; Dafna D Gladman; Vincent Piguet; Lihi Eder
Journal:  Arthritis Rheumatol       Date:  2022-05-16       Impact factor: 15.483

4.  Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis.

Authors:  Thao H P Nguyen; Morten Wang Fagerland; Gia Deyab; Gunnbjørg Hjeltnes; Ivana Hollan; Mark W Feinberg; Gro Ø Eilertsen; Knut Mikkelsen; Stefan Agewall
Journal:  PLoS One       Date:  2021-06-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.